🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Newsweek has ranked Cleveland Clinic as the #2 hospital in the world. This recognition is a reflection of our caregivers, who form the heart and soul of our organization. Their dedication to excellence and compassion are the pillars of our care. More: bit.ly/43n8n05

I really enjoyed recording this - and (off the record) I learned that Wallace is interested in the history of Queens Square - and that it was named for Queen Charlotte. (...who didn't invent the QS reflex hammer, but I'd be delighted if they put that in Bridgerton)

Pleased to have contributed in a small way to this expanded access to cladribine as a NICE advisor with Prof Ruth Dobson ⁦Ruth Dobson⁩ theguardian.com/society/2025/m…

The number of patients entering clinical trials in the UK fell by 27% from 2018 to 2023 and new industry trials declined 38%. To revive clinical research we need to streamline systems and dismantle bureaucracy, writes Masud Husain bmj.com/content/388/bm…

Climate change poses significant challenges for people with #MultipleSclerosis, with heat exacerbating symptoms, air pollution contributing to neuroinflammation, and mobility impairments complicating resource access. Topical review from Harvard Medical School ▶️ journals.sagepub.com/doi/abs/10.117…

Lots of work went into this one! Understanding the spinal cord will help us better target progression. great work Kedar Mahajan Cleveland Clinic Neurodegeneration and Demyelination in the MS Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives hubs.la/Q03c-9HP0

Our latest research is in Nature Communications led by Philipp Goebl. Enabling insights from routine care MRI acquisitions. Check out the full paper here 👉 nature.com/articles/s4146… #MultipleSclerosis #MRI #DeepLearning #AIinMedicine

Diagnosis and Management of Children With Atypical Neuroinflammation hubs.la/Q03gV2QN0

Did you know that uveitis (especially intermediate uveitis with venous vasculitis) can precede and be associated with later diagnosis of #multiplesclerosis? And vice versa. Published online first, our team review shares exciting new epi insights from UK tandfonline.com/doi/full/10.10…

#AHSCT in #MS. At #ImperialCollegeHealthcareNHS Trust, we compared clinical and radiological outcomes among #RRMS patients who received AHSCT and two highly effective disease modifying treatments, #Alemtuzumab and #Ocreluzumab. Read results 👇 doi.org/10.1002/ana.27…

From reactive to proactive: Lived experience and the nursing role in #multiplesclerosis care. MS Academy will host a webinar in partnership with MS-UK - Multiple Sclerosis Charity and RCN Neuroscience Forum specifically for all nurses caring for people with MS. 🗓️ Thu 22nd May at 16:00 eu1.hubs.ly/H0jvJFr0

This week's #MSAwarenessWeek is all about conversations & collaboration. We know that meaningful conversations lead to better care, whether it’s between a HCP and a person with MS, or between healthcare services and charities. Read more: eu1.hubs.ly/H0jP8NJ0 #MSConversations

Welcome to Sheffield for the MS Foundation MasterClass 21! It's great to have so many healthcare professionals here who want to learn about #multiplesclerosis as a specialism. Wallace Brownlee #multiplesclerosisMC

A dynamic MDT session at MS Foundation MasterClass 21 with Dr Rhian Raftopoulos and Ray Dorsey, exploring disease modifying therapies through practical case studies. #multiplesclerosisMC

Can the central vein sign offer an alternative to lumbar punctures?#MS Check out our latest results from a multi-centre, prospective study of 99 ppl presenting with typical CIS. We report not only sensitivity analyses but also discuss patient preferences. neurology.org/doi/10.1212/WN…

We’re delighted to share that Dr Ed Richfield is stepping into the role of academic director for the #Parkinsons Advanced MasterClass, starting with this week’s MasterClass 48 module 1! Read the full article on our website: eu1.hubs.ly/H0kbVmx0

Did you publish your first article as first author in 2024 on our journals? Apply to the 2025 F2 Award of MSJ and ECTRIMS with a cash prize and one year access to the #MSJ (stay tuned at the #ECTRIMS2025 Closing Ceremony) ▶️ journals.sagepub.com/msj/researcher… Deadline: Jul 19

This study identified factors associated with relapses in neurosarcoidosis. Learn more: hubs.la/Q03pRxCl0

🚀 Kudos to the faculty & participants for making the 2025 Summer School a success! Over the last 3 days, attendees truly honed their skills in visual pathway assessments through hands-on workshops & expert-led lectures. Stay tuned - webcasts are coming to myECTRIMS soon. #MS

Important to see this published: tinyurl.com/3skcvyn7. Through a UK wide collaboration (including Ruth Dobson Wallace Brownlee Ray Dorsey amongst others) we demonstrated discordance between the JCV testing available with biosimilar Natalizumab versus originator Natalizumab.